Cardiac troponin T versus cardiac troponin I for mortality risk prediction: Is one biomarker better than the other?

doi:10.1016/j.clinbiochem.2020.02.003

Clinical Biochemistry

Volume 78, April 2020, Pages 40-41

https://doi.org/10.1016/j.clinbiochem.2020.02.003 Get rights and content

Section snippets

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References (5)

S.H. Tveit et al.
Superiority of high sensitivity cardiac troponin T vs. I for long-term prognostic value in patients with chest pain; data from the Akershus cardiac Examination (ACE) 3 study
Clin. Biochem.
(2020)
N. van der Linden et al.
Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis
Medicine (Baltimore)
(2016)

There are more references available in the full text version of this article.

Cited by (6)

Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry
2022, European Journal of Cancer
Citation Excerpt :
There have also been reports of vasculitis [4], which along with plaque destabilisation can be viewed as a greater degree of immune activation affecting multiple organs and systems, which has been related to greater mortality [13]. Consequently, patients undergoing coronary revascularization in our cohort potentially suffered from both a potentially more intense myocarditis as well as myocardial ischaemia, leading to higher myocardial damage as observed with an elevated troponin level, and thus, increased mortality [22]. From a diagnostic perspective, discriminating ICB-myocarditis from myocardial infarction may be guided by the following discriminative features.
Immune checkpoint blocker (ICB) associated myocarditis (ICB-myocarditis) may present similarly and/or overlap with other cardiac pathology including acute coronary syndrome presenting a challenge for prompt clinical diagnosis.
An international registry was used to retrospectively identify cases of ICB-myocarditis. Presence of coronary artery disease (CAD) was defined as coronary artery stenosis >70% in patients undergoing coronary angiogram.
Among 261 patients with clinically suspected ICB-myocarditis who underwent a coronary angiography, CAD was present in 59/261 patients (22.6%). Coronary revascularization was performed during the index hospitalisation in 19/59 (32.2%) patients. Patients undergoing coronary revascularization less frequently received steroids administration within 24 h of admission compared to the other groups (p = 0.029). Myocarditis-related 90-day mortality was 9/17 (52.7%) in the revascularised cohort, compared to 5/31 (16.1%) in those not revascularized and 25/156 (16.0%) in those without CAD (p = 0.001). Immune-related adverse event-related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 6/31 (19.4%) in those not revascularized and 31/156 (19.9%) in no CAD groups (p = 0.007). All-cause 90-day mortality was 11/17 (64.7%) in the revascularized cohort, compared to 13/31 (41.9%) in no revascularization and 60/158 (38.0%) in no CAD groups (p = 0.10). After adjustment of age and sex, coronary revascularization remained associated with ICB-myocarditis-related death at 90 days (hazard ratio [HR] = 4.03, 95% confidence interval [CI] 1.84–8.84, p < 0.001) and was marginally associated with all-cause death (HR = 1.88, 95% CI, 0.98–3.61, p = 0.057).
CAD may exist concomitantly with ICB-myocarditis and may portend a poorer outcome when revascularization is performed. This is potentially mediated through delayed diagnosis and treatment or more severe presentation of ICB-myocarditis.
Impact of high-sensitivity troponin elevation and dynamic changes on 90-day mortality in patients with acute ischemic stroke after mechanical thrombectomy: Results from an observational cohort
2023, Journal of NeuroInterventional Surgery
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis
2023, Circulation
Discrepancies of cardio-muscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor (ICI)-associated myocarditis
2022, Research Square
A comparison of modelled serum cTnT and cTnI kinetics after 60 min swimming
2022, Biomarkers
Predictive ability of EuroSCORE II integrating cardiactroponin T in patients undergoing OPCABG
2020, BMC Cardiovascular Disorders

View full text

Letter to the EditorCardiac troponin T versus cardiac troponin I for mortality risk prediction: Is one biomarker better than the other?

Section snippets

Declaration of Competing Interest

Superiority of high sensitivity cardiac troponin T vs. I for long-term prognostic value in patients with chest pain; data from the Akershus cardiac Examination (ACE) 3 study

Clin. Biochem.

Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis

Medicine (Baltimore)

Letter to the Editor
Cardiac troponin T versus cardiac troponin I for mortality risk prediction: Is one biomarker better than the other?